A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...

A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...

Richter transformation develops in 2%–10% of CLL cases, often with rapid clinical decline, limited chemotherapy efficacy, and ...

Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...

A peer-reviewed study published in Cell in March 2026 introduces “optovolution,” an in vivo directed-evolution system that uses light to breed proteins capable of switching between active and inactive ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar ...

New research from Memorial Sloan Kettering Cancer Center (MSK) finds the TCA cycle’s waste-management function may present an opportunity against cancer; shows how microplastics impair immune ...

A fleeting DNA fold called i‑DNA can switch cancer‑related genes on and off, revealing a hidden structural weak point that ...

Leerink Global Healthcare Conference 2026 March 10, 2026 11:20 AM EDTCompany ParticipantsDietmar Berger - Chief ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 2:30 PM ESTCompany ParticipantsDave Gancarz - Chief Business ...

The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with multi-specific (i.e.